In conclusion, AIT represents a uniquely positioned, disease-modifying strategy in the management of AA, with potential benefits spanning symptom control, prevention of disease onset and progression, and long-term benefits persisting after treatment discontinuation.
Francesco Catamerò, Simone Foti Randazzese, D. Caimmi et al.· Biologics : Targets & Therap...· 0 citations
The findings highlight the biological relevance of epigenetic modifications in cystic fibrosis and support systemic inflammation as a common driver of differential DNA methylation across inflammatory diseases.
Loréna Valdés, Jörg Tost, I. Rivals et al.· Respiratory Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.